Share on StockTwits

Perrigo Company PLC (NASDAQ:PRGO) has earned an average rating of “Buy” from the fourteen ratings firms that are currently covering the stock, American Banking & Market News reports. Three equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $166.25.

Perrigo Company PLC (NASDAQ:PRGO) opened at 143.28 on Wednesday. Perrigo Company PLC has a 52-week low of $115.94 and a 52-week high of $168.39. The stock has a 50-day moving average of $150.0 and a 200-day moving average of $149.3. The company has a market cap of $19.171 billion and a price-to-earnings ratio of 77.69.

A number of analysts have recently weighed in on PRGO shares. Analysts at Deutsche Bank initiated coverage on shares of Perrigo Company PLC in a research note on Tuesday, July 22nd. They set a “buy” rating and a $189.00 price target on the stock. Separately, analysts at Morgan Stanley downgraded shares of Perrigo Company PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 11th. Finally, analysts at Argus cut their price target on shares of Perrigo Company PLC from $175.00 to $160.00 in a research note on Thursday, May 15th. They now have a “buy” rating on the stock.

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (NASDAQ:PRGO) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.